Heart failure & cardiomyopathiesRandomised controlled trial
Colchicine in acutely decompensated heart failure: the COLICA trial
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
Authors' conclusion
Colchicine was safe and effective in reducing inflammation in patients with AHF; however, colchicine and placebo exhibited comparable effects on reducing NT-proBNP and preventing new worsening heart failure events.
Study context
- Population
- Patients with acute HF requiring ≥40 mg IV furosemide, regardless of left ventricular ejection fraction (LVEF), inpatient or outpatient
- Participants
- 278 patients
- Comparison
- Colchicine vs placebo
- Colchicinen = 141
- Placebon = 137reference
- Primary endpoint
- Time-averaged reduction in NT-proBNP levels
- Follow-up
- 8 weeks
Primary result
Time-averaged reduction in NT-proBNP
Ratio of change
1.0
By group
Colchicine
−62.2%
95% CI −68.9%–-54.2%
Placebo
−62.1%
95% CI −68.6%–-54.3%
As reported in the abstract
Further findings
New worsening HF episodes
P = 0.698
| Outcome | ratio of change | P value |
|---|---|---|
| C-reactive protein | 0.60 | P < 0.001 |
| Interleukin-6 | 0.72 | P = 0.019 |
Need for IV furosemide during follow-up
- Lower with colchicine
- P = 0.043
Safety
Medication withdrawal
Medication withdrawal
- Diarrhea slightly more common with colchicine
Original publication
Colchicine in acutely decompensated heart failure: the COLICA trial. Eur Heart J. Published 30 August 2024. doi:10.1093/eurheartj/ehae538
Summarised from the published abstract; every number is checked against it